期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 24, 期 1, 页码 230-238出版社
WILEY
DOI: 10.1002/ejhf.2386
关键词
Heart failure; Potassium; Hyperkalaemia; Patiromer; Renin-angiotensin-aldosterone system inhibitors; Mineralocorticoid receptor antagonists; Adherence; Trial design
资金
- Vifor Pharma
The DIAMOND trial aims to assess the impact of patiromer on K+ control in patients with HFrEF and hyperkalaemia or a history of hyperkalaemia compromising RAASi therapy, to improve RAASi use.
Aims In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+) binder, may improve serum K+ levels and adherence to RAASi. Methods The DIAMOND trial will enroll similar to 820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction <= 40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to >= 50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi use score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive heart failure medication. Conclusion The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据